WO2006094073A3 - Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands - Google Patents

Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands Download PDF

Info

Publication number
WO2006094073A3
WO2006094073A3 PCT/US2006/007304 US2006007304W WO2006094073A3 WO 2006094073 A3 WO2006094073 A3 WO 2006094073A3 US 2006007304 W US2006007304 W US 2006007304W WO 2006094073 A3 WO2006094073 A3 WO 2006094073A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor tyrosine
tyrosine kinase
bret
assay
identify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/007304
Other languages
French (fr)
Other versions
WO2006094073A2 (en
Inventor
Hans Schiffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Priority to EP06736597A priority Critical patent/EP1864130A2/en
Publication of WO2006094073A2 publication Critical patent/WO2006094073A2/en
Publication of WO2006094073A3 publication Critical patent/WO2006094073A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed herein are methods of evaluating whether a test compound functions as a ligand for a receptor tyrosine kinase. Also provided are methods of making pharmaceutical compositions that include agonists, antagonists, or inverse agonists of receptor tyrosine kinases. Also provides are isolated cells that include a receptor tyrosine kinase and a second protein, wherein the receptor tyrosine kinase contains a fluorescent donor moiety and the second protein contains a fluorescent acceptor moiety.
PCT/US2006/007304 2005-03-02 2006-03-01 Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands Ceased WO2006094073A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06736597A EP1864130A2 (en) 2005-03-02 2006-03-01 Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65831905P 2005-03-02 2005-03-02
US60/658,319 2005-03-02

Publications (2)

Publication Number Publication Date
WO2006094073A2 WO2006094073A2 (en) 2006-09-08
WO2006094073A3 true WO2006094073A3 (en) 2007-01-11

Family

ID=36677190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007304 Ceased WO2006094073A2 (en) 2005-03-02 2006-03-01 Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands

Country Status (3)

Country Link
US (1) US20060199226A1 (en)
EP (1) EP1864130A2 (en)
WO (1) WO2006094073A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801407B (en) 2007-06-05 2013-12-18 耶鲁大学 Receptor tyrosine kinase inhibitors and methods of use thereof
MX2010008025A (en) * 2008-01-22 2010-08-04 Biogen Idec Inc Ron antibodies and uses thereof.
US8067155B2 (en) * 2008-08-18 2011-11-29 Discoverx Corporation Receptor tyrosine kinase assays
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
EP3133167B1 (en) * 2009-05-15 2018-09-12 Insight Genetics, Inc. Methods relating to fusions of alk for diagnosing cancer
EP2504024A2 (en) * 2009-09-27 2012-10-03 Ruhr-Universität Bochum Method for the therapy and diagnosis of alzheimer's disease
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2558575B1 (en) * 2010-04-13 2015-12-16 Sigma-Aldrich Co. LLC Methods for generating endogenously tagged protein
WO2012012738A1 (en) 2010-07-23 2012-01-26 Sigma-Aldrich Co., Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6467395B2 (en) * 2016-11-25 2019-02-13 キヤノン株式会社 Image transmitting apparatus, image receiving apparatus, control method therefor, and image communication system
JP7524158B2 (en) * 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Nucleic acid constructs encoding Trk fragments and uses thereof
US20230332147A1 (en) * 2020-09-09 2023-10-19 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing growth factor receptor bound protein 10 (grb10) or growth factor receptor bound protein 14 (grb14) in the liver
WO2024238764A2 (en) * 2023-05-16 2024-11-21 The Regents Of The University Of California Bioinformatically-identified control elements for regulated expression of a lentiviral vector to treat x-linked lymphoproliferative disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214227A1 (en) * 1999-12-22 2004-10-28 Erik Joly Bioluminescence resonance energy transfer (bret) fusion molecule and method of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214227A1 (en) * 1999-12-22 2004-10-28 Erik Joly Bioluminescence resonance energy transfer (bret) fusion molecule and method of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "EGF receptor", 12 March 2005 (2005-03-12), Human Protein Reference Database, pages 1 - 4, XP002392111, Retrieved from the Internet <URL:http://www.hprd.org/protein/00579?selectedtab=INTERACTIONS> [retrieved on 20060726] *
BOUTE NICOLAS ET AL: "The use of resonance energy transfer in high-throughput screening: BRET versus FRET.", TRENDS IN PHARMACOLOGICAL SCIENCES. AUG 2002, vol. 23, no. 8, August 2002 (2002-08-01), pages 351 - 354, XP004386171, ISSN: 0165-6147 *
BUERGER CLAUDIA ET AL: "Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 39, 26 September 2003 (2003-09-26), pages 37610 - 37621, XP002392110, ISSN: 0021-9258 *
ISSAD T ET AL: "Looking for an insulin pill? Use the BRET methodology!", DIABETES & METABOLISM. APR 2003, vol. 29, no. 2 Pt 1, April 2003 (2003-04-01), pages 111 - 117, XP002392109, ISSN: 1262-3636 *
MINOR LISA K: "Assays to measure the activation of membrane tyrosine kinase receptors: focus on cellular methods.", CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT. SEP 2003, vol. 6, no. 5, September 2003 (2003-09-01), pages 760 - 765, XP008067040, ISSN: 1367-6733 *

Also Published As

Publication number Publication date
EP1864130A2 (en) 2007-12-12
WO2006094073A2 (en) 2006-09-08
US20060199226A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
WO2006094073A3 (en) Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
WO2007131191A3 (en) Mass spectrometry methods for multiplexed quantification of protein kinases and phosphatases
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2006099050A3 (en) Polar dyes
DE122012000043I1 (en) Pyrrolo [2,3-B] pyridine derivatives as protein kinase inhibitors.
WO2007120699A3 (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds &amp; other chemicals
WO2007141626A8 (en) Circulating tumor cell assay
JP2006225396A5 (en)
WO2008014280A3 (en) Flourescent dyes for use in glucose sensing
WO2008082713A3 (en) Integrated semiconductor bioarray
WO2005113596A3 (en) Cell surface receptor isoforms and methods of identifying and using the same
WO2007035633A3 (en) Screening assays and methods
WO2005026730A3 (en) Multiplex binding and activity assays
WO2003102578A3 (en) High throughput cellular response assay using microarrays
WO2004079326A3 (en) Anaplastic lymphoma kinase assay, reagents and compositions thereof
WO2007051207A3 (en) Kinase and ubiquination assays
WO2009007846A3 (en) Methods for modifying, isolating, detecting, visualizing, and quantifying citrullinated and/or homocitrullinated peptides, polypeptides and proteins
NO20060775L (en) Muscarine acetylcholine receptor antagonists
DE602004015953D1 (en) SOLID PHASE IMMUNOCHROMATOGRAPHIC TEST PROCEDURE
WO2005114219A3 (en) Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
SG129428A1 (en) Generic kinase assay
WO2009085805A3 (en) Circulating epha2 receptor
Sicard et al. A fluorescent reporter of ATP binding-competent receptor kinases
WO2004039963A3 (en) Antibodies specific for phosphorylated insulin receptor substrate-1/2 (ser 1101/ser1149) and uses thereof
ATE466884T1 (en) HOLO-TRANSCOBALAMIN BINDING PARTNERS AND THEIR USE IN COBALAMINE TESTING

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006736597

Country of ref document: EP